Total Payments
$512,889
2024 Payments
$38,900
Companies
23
Transactions
603
Medicare Patients
181
Medicare Billing
$17,677
Payment Breakdown by Category
Consulting$271,805 (53.0%)
Other$101,972 (19.9%)
Travel$89,692 (17.5%)
Research$41,384 (8.1%)
Food & Beverage$7,873 (1.5%)
Education$163.77 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $271,805 | 102 | 53.0% |
| Travel and Lodging | $89,692 | 213 | 17.5% |
| Honoraria | $68,683 | 33 | 13.4% |
| Unspecified | $41,384 | 24 | 8.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,289 | 25 | 6.5% |
| Food and Beverage | $7,873 | 202 | 1.5% |
| Education | $163.77 | 4 | 0.0% |
Payments by Type
General
$471,506
579 transactions
Research
$41,384
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $102,567 | 168 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $98,372 | 88 | $0 (2024) |
| PFIZER INC. | $87,886 | 66 | $0 (2024) |
| UCB SA | $57,943 | 31 | $0 (2023) |
| UCB, Inc. | $34,724 | 18 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $30,598 | 87 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $22,217 | 57 | $0 (2023) |
| Janssen Global Services, LLC | $16,200 | 9 | $0 (2023) |
| Lilly USA, LLC | $15,505 | 15 | $0 (2024) |
| Eli Lilly and Company | $10,418 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $38,900 | 79 | Janssen Scientific Affairs, LLC ($13,157) |
| 2023 | $56,569 | 94 | PFIZER INC. ($13,641) |
| 2022 | $56,489 | 77 | UCB, Inc. ($17,710) |
| 2021 | $51,867 | 23 | PFIZER INC. ($24,489) |
| 2020 | $90,962 | 39 | Novartis Pharmaceuticals Corporation ($28,933) |
| 2019 | $52,726 | 107 | Novartis Pharmaceuticals Corporation ($29,622) |
| 2018 | $82,474 | 110 | AbbVie, Inc. ($49,415) |
| 2017 | $82,902 | 74 | AbbVie, Inc. ($30,979) |
All Payment Transactions
603 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $3,262.50 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $47.30 | General |
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $9.44 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $154.76 | General |
| 11/18/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/18/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/18/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.14 | General |
| Category: Immunology | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.29 | General |
| 11/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $137.40 | General |
| Category: Dermatology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $81.48 | General |
| 11/16/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | In-kind items and services | $56.42 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 11/16/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,006.40 | General |
| 11/15/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $2,960.00 | General |
| 11/15/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,081.60 | General |
| Category: Immunology | ||||||
| 11/15/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $127.42 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $93.95 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,710 | 5 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKI | UCB, Inc. | $6,800 | 1 |
| Publication support research related | Novartis Pharma AG | $4,470 | 2 |
| A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJE | UCB, Inc. | $3,940 | 1 |
| A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATETHE EFFICACY AND SAFETY OF BIMEKI | UCB, Inc. | $3,520 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,356 | 3 |
| CAIN457F2342 | Novartis Pharmaceuticals Corporation | $2,035 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $1,641 | 1 |
| A MULTICENTER, OPEN-LABEL, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN SUBJECTS WITH PSORIATIC ARTHRITIS | UCB, Inc. | $1,240 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,200 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,176 | 2 |
| TOFACITINIB SPA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTICENTER STUDY OF SUBCUTANEOUS SECUKINUMAB IN PREFILLED SYRINGES TO DEMONSTRATE THE EFFICACY AT 24 WEEKS AND TO ASSESS THE LONG TERM EFFICACY SAFETY AND TOLERABILITY UP TO 5 YEARS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS | Novartis Pharmaceuticals Corporation | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 18 | $3,539 | $1,319 |
| 2022 | 1 | 15 | 26 | $4,732 | $1,899 |
| 2021 | 1 | 68 | 113 | $21,012 | $7,729 |
| 2020 | 2 | 85 | 126 | $23,905 | $6,730 |
Total Patients
181
Total Services
283
Medicare Billing
$17,677
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 18 | $3,539 | $1,319 | 37.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 26 | $4,732 | $1,899 | 40.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 68 | 113 | $21,012 | $7,729 | 36.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 109 | $21,056 | $5,773 | 27.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 16 | 17 | $2,849 | $957.47 | 33.6% |
About Dr. Christopher Ritchlin, MD
Dr. Christopher Ritchlin, MD is a Internal Medicine healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497775472.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Ritchlin, MD has received a total of $512,889 in payments from pharmaceutical and medical device companies, with $38,900 received in 2024. These payments were reported across 603 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($271,805).
As a Medicare-enrolled provider, Ritchlin has provided services to 181 Medicare beneficiaries, totaling 283 services with total Medicare billing of $17,677. Data is available for 4 years (2020–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Rochester, NY
- Active Since 07/20/2006
- Last Updated 07/03/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1497775472
Products in Payments
- Humira (Biological) $71,566
- COSENTYX (Biological) $65,246
- TREMFYA (Drug) $55,059
- XELJANZ (Drug) $44,644
- ORENCIA (Biological) $12,065
- Cimzia (Drug) $7,395
- Rituxan (Biological) $7,391
- Bimzelx (Biological) $3,960
- KEVZARA (Drug) $2,773
- TALTZ (Drug) $2,405
- COSENTYX (Drug) $2,293
- RINVOQ (Biological) $624.35
- RINVOQ (Drug) $600.00
- OTREXUP (Drug) $475.43
- SECUKINUMAB_COSENTYX_DERMATOLOGY (Biological) $352.14
- SIMPONI ARIA (Biological) $250.00
- Otezla (Drug) $115.07
- Enbrel (Biological) $91.69
- ILUMYA (Biological) $82.00
- REMICADE (Biological) $52.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Rochester
Dr. Ben George, M.d, M.D
Internal Medicine — Payments: $729,795
Internal Medicine $729,795
John Kisiel, M.d, M.D
Internal Medicine — Payments: $550,377
Internal Medicine $550,377
Gregory Poland, M.d, M.D
Internal Medicine — Payments: $532,099
Internal Medicine $532,099
Scott Feitell, D.o, D.O
Internal Medicine — Payments: $471,187
Internal Medicine $471,187
Prashant Kapoor, Md, MD
Internal Medicine — Payments: $403,295
Internal Medicine $403,295
Irina Bancos, M.d, M.D
Internal Medicine — Payments: $360,053
Internal Medicine $360,053